Jan 23, 2019 Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference Learn More
Jan 7, 2019 Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma Learn More